0.27Open0.27Pre Close0 Volume26 Open Interest1.00Strike Price0.00Turnover248.79%IV22.34%PremiumDec 20, 2024Expiry Date0.06Intrinsic Value100Multiplier23DDays to Expiry0.21Extrinsic Value100Contract SizeAmericanOptions Type-0.4118Delta0.6550Gamma3.48Leverage Ratio-0.0049Theta-0.0004Rho-1.43Eff Leverage0.0009Vega
Tempest Therapeutics Stock Discussion
13/11/2024 - 05:21
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial
Received final funding approval from NCI to move TPST-1495 into a Phas...
12/11/2024 - 21:00
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter fro...
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
No comment yet